X0306 4 2015-11-11 0001411685 VistaGen Therapeutics, Inc. VSTA 0001415876 SNODGRASS H. RALPH C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 true true false false PRES./CHIEF SCIENTIFIC OFFICER Warrant for Common Stock 12.8 2015-11-11 4 D 0 50000 0 D 2015-04-01 2023-03-03 Common Stock 50000 0 D Warrant for Common Stock 7 2015-11-11 4 A 0 50000 0 A 2015-04-01 2023-03-03 Common Stock 50000 50000 D Warrant for Common Stock 10 2015-11-11 4 D 0 2500 0 D 2019-03-19 Common Stock 2500 0 D Warrant for Common Stock 7 2015-11-11 4 A 0 2500 0 A 2019-03-19 Common Stock 2500 2500 D Warrant for Common Stock 10 2015-11-11 4 D 0 7500 0 D 2019-03-19 Common Stock 7500 0 D Warrant for Common Stock 7 2015-11-11 4 A 0 7500 0 A 2019-03-19 Common Stock 7500 7500 D Warrant for Common Stock 10 2015-11-11 4 D 0 100000 0 D 2015-01-11 2020-01-11 Common Stock 100000 0 D Warrant for Common Stock 7 2015-11-11 4 A 0 100000 0 A 2015-01-11 2020-01-11 Common Stock 100000 100000 D Warrant for Common Stock 9.25 2015-11-11 4 D 0 150000 0 D 2015-09-02 2020-09-02 Common Stock 150000 0 I By Trust Warrant for Common Stock 7 2015-11-11 4 A 0 150000 0 A 2015-09-02 2020-09-02 Common Stock 150000 150000 I By Trust The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on March 3, 2013. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on March 19, 2014. Subject to the Reporting Person's continuous service, and as incentive to continue employment and build shareholder value, the Warrant will vest according to the following schedule: 50% of the total number of shares on April 1, 2014 (the "Vesting Start Date"); 25% of the total number of shares on the one year anniversary of the Vesting Start Date; and 25% of the total number of shares on the two year anniversary of the Vesting Start Date; provided, however, that the Warrant shall vest in full upon a change in control of the Company, or upon the consummation by the Company and a third-party of a license or sale transaction involving at least one (1) new drug rescue variant developed by the Company. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on January 11, 2015. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the old warrant and the grant of a replacement warrant. The warrant was originally granted on September 2, 2015. Held by the H. Ralph Snodgrass Living Trust, dated 10/2/2008 /s/ Jerrold D. Dotson, Attorney-in-Fact 2015-11-13